KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Gains from Investment Securities (2016 - 2025)

NovoCure's Gains from Investment Securities history spans 12 years, with the latest figure at $35.8 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 6145.47% year-over-year to $35.8 million; the TTM value through Dec 2025 reached $29.4 million, up 497.15%, while the annual FY2025 figure was $29.4 million, 497.15% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $35.8 million at NovoCure, up from -$25.3 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $35.8 million in Q4 2025 and bottomed at -$25.3 million in Q3 2025.
  • The 5-year median for Gains from Investment Securities is $888000.0 (2023), against an average of $2.4 million.
  • The largest annual shift saw Gains from Investment Securities surged 8456.62% in 2022 before it plummeted 1629.45% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at -$136000.0 in 2021, then soared by 8456.62% to $11.4 million in 2022, then increased by 10.55% to $12.6 million in 2023, then tumbled by 95.43% to $574000.0 in 2024, then skyrocketed by 6145.47% to $35.8 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Gains from Investment Securities are $35.8 million (Q4 2025), -$25.3 million (Q3 2025), and $21.4 million (Q2 2025).